Mark G. Ward

1.1k total citations
45 papers, 553 citations indexed

About

Mark G. Ward is a scholar working on Genetics, Epidemiology and Immunology. According to data from OpenAlex, Mark G. Ward has authored 45 papers receiving a total of 553 indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Genetics, 24 papers in Epidemiology and 16 papers in Immunology. Recurrent topics in Mark G. Ward's work include Inflammatory Bowel Disease (31 papers), Microscopic Colitis (23 papers) and Acute Lymphoblastic Leukemia research (9 papers). Mark G. Ward is often cited by papers focused on Inflammatory Bowel Disease (31 papers), Microscopic Colitis (23 papers) and Acute Lymphoblastic Leukemia research (9 papers). Mark G. Ward collaborates with scholars based in Australia, United Kingdom and France. Mark G. Ward's co-authors include Miles Sparrow, Xavier Roblin, Peter M. Irving, Peter R. Gibson, Jeremy Sanderson, D Metcalf, Klaus Geißler, P. Mayer, Kirstin M. Taylor and Viraj C. Kariyawasam and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and Gastroenterology.

In The Last Decade

Mark G. Ward

43 papers receiving 540 citations

Peers

Mark G. Ward

GENET

EPIDE

IMMUN

PHEOH

SURGE

Michael C. Stephens United States

Virginia Solitano Italy

Pantelis Karatzas Greece

Gherardo Tapete Italy

Paula Ministro Portugal

Frank Czul United States

Richard A. Lirio United States

Nikolas Plevris United Kingdom

Timothy E. Ritter United States

Giammarco Mocci Italy

Michael C. Stephens United States

Mark G. Ward

375 ×1.0

GENET

284 ×1.1

EPIDE

130 ×0.7

IMMUN

94 ×1.0

PHEOH

143 ×1.7

SURGE

Citations per year, relative to Mark G. Ward Mark G. Ward (= 1×) peers Michael C. Stephens

Countries citing papers authored by Mark G. Ward

Since Specialization

Citations

This map shows the geographic impact of Mark G. Ward's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark G. Ward with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark G. Ward more than expected).

Fields of papers citing papers by Mark G. Ward

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark G. Ward. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark G. Ward. The network helps show where Mark G. Ward may publish in the future.

Co-authorship network of co-authors of Mark G. Ward

This figure shows the co-authorship network connecting the top 25 collaborators of Mark G. Ward. A scholar is included among the top collaborators of Mark G. Ward based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark G. Ward. Mark G. Ward is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gibson, David, et al.. (2025). Review Article: Albumin and Its Role in Inflammatory Bowel Disease: The Old, the New, and the Future. Journal of Gastroenterology and Hepatology. 40(4). 808–820. 2 indexed citations

Ward, Mark G., et al.. (2024). Mimics of inflammatory bowel disease: commonly encountered differentials of an uncommon condition. The Medical Journal of Australia. 221(3). 136–139.

Zhang, Fan, Susan J. Connor, Alex Boussioutas, et al.. (2024). Pathogenesis and precision medicine for predicting response in inflammatory bowel disease: advances and future directions. SHILAP Revista de lepidopterología. 2(1). e100006–e100006. 14 indexed citations

Paramsothy, Sudarshan, Viraj C. Kariyawasam, Ramesh Paramsothy, et al.. (2024). Effects of Thiopurine Withdrawal on Vedolizumab-Treated Patients With Ulcerative Colitis: A Randomized Controlled Trial. Clinical Gastroenterology and Hepatology. 22(11). 2299–2308.e5. 8 indexed citations

Reynolds, Rebecca M., David Gibson, Miles Sparrow, et al.. (2023). Adalimumab Drug Levels at Secondary Loss of Response Do Not Predict Response to Dose-intensification in Crohn’s Disease: A Retrospective, International Multicenter Study. Inflammatory Bowel Diseases. 30(10). 1714–1723. 3 indexed citations

Johnson, Douglas, John Halliday, Robert V. Bryant, et al.. (2021). SARS‐CoV‐2 vaccination in patients with inflammatory bowel disease. PubMed. 3(4). 212–228. 8 indexed citations

Ward, Mark G., et al.. (2021). De-escalation from Dose-Intensified Anti-TNF Therapy Is Successful in the Majority of IBD Patients at 12 Months. Digestive Diseases and Sciences. 67(1). 259–262. 4 indexed citations

Ward, Mark G., Ourania Rosella, Gennaro Rosella, Catherine Martin, & Peter G. Gibson. (2021). Comparison of SB2-Infliximab With Originator-Infliximab in the Measurement of Serum Concentrations: A Short Communication. Therapeutic Drug Monitoring. 43(5). 692–695. 2 indexed citations

Ward, Mark G., Miles Sparrow, & Xavier Roblin. (2018). Therapeutic drug monitoring of vedolizumab in inflammatory bowel disease: current data and future directions. Therapeutic Advances in Gastroenterology. 11. 3971961650–3971961650. 43 indexed citations

10.

Ward, Mark G., Lauren Beswick, Gennaro Rosella, et al.. (2017). Intra‐patient variability in adalimumab drug levels within and between cycles in Crohn's disease. Alimentary Pharmacology & Therapeutics. 45(8). 1135–1145. 30 indexed citations

11.

Kariyawasam, Viraj C., Mark G. Ward, Paul Blaker, et al.. (2017). Thiopurines Dosed to a Therapeutic 6-Thioguanine Level in Combination with Adalimumab Are More Effective Than Subtherapeutic Thiopurine-based Combination Therapy or Adalimumab Monotherapy During Induction and Maintenance in Patients with Long-standing Crohnʼs Disease. Inflammatory Bowel Diseases. 23(9). 1555–1565. 18 indexed citations

12.

Ward, Mark G., Ben Warner, Sai Wei Chuah, et al.. (2017). Infliximab and adalimumab drug levels in Crohn's disease: contrasting associations with disease activity and influencing factors. Alimentary Pharmacology & Therapeutics. 46(2). 150–161. 51 indexed citations

13.

Ward, Mark G., et al.. (2016). PTH-074 The Presence of Total Anti-Drug Antibodies to Biologic Drugs Does not Adversely Affect Long-Term Outcomes in Crohn’s Disease Patients with Adequate Drugs Levels and Absent Free Anti-Drug Antibodies. A255–A256. 2 indexed citations

14.

Ward, Mark G., et al.. (2015). PTU-078 A prospective evaluation of adalimumab drug levels and anti-drug antibodies using two commercial elisa and the influence of 6-thioguanine nucleotides amongst patients with inflammatory bowel disease. A95.1–A95. 1 indexed citations

15.

Ward, Mark G., et al.. (2014). PWE-111 Higher Red Blood Cell Methotrexate Polyglutamates Correlate With Increased Disease Activity, And Are Useful In Assessing Adherence. Gut. 63(Suppl 1). A173.1–A173. 2 indexed citations

16.

Goel, Rajeev, et al.. (2014). PTU-087 Indeterminate And Inconclusive Results Are Common When Using Interferon Gamma Release Assay As Screening For Tb In Patients With Ibd. Gut. 63(Suppl 1). A77.2–A77.

17.

Goel, Rishi, Mark G. Ward, Kamal Patel, et al.. (2014). Su1101 Indeterminate and Inconclusive Results Are Common When Using Interferon Gamma Release Assay As Screening for TB in Patients With IBD. Gastroenterology. 146(5). S–374. 1 indexed citations

18.

Ward, Mark G. & Peter M. Irving. (2014). Role of therapeutic drug monitoring for biologics in IBD. Research Portal (King's College London). 14(2). 44–53. 1 indexed citations

19.

Duncan, John S., James B. Canavan, Mark G. Ward, et al.. (2013). PWE-080 Prevalence of Faecal Incontinence in Adults with Inflammatory Bowel Disease. Gut. 62(Suppl 1). A162.3–A163. 3 indexed citations

20.

Langenberg, Daniel R. van, et al.. (2009). The potential value of faecal lactoferrin as a screening test in hospitalized patients with diarrhoea. Internal Medicine Journal. 40(12). 819–827. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact